v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue $ 135 $ 108 $ 151 $ 433
Cost of revenue 30 38 30 199
Gross profit 105 70 121 234
Operating expenses:        
Research and development 1,733 1,315 4,701 4,248
General and administrative 4,774 6,505 15,477 20,256
Depreciation and amortization 84 51 210 142
Total operating expenses 6,591 7,871 20,388 24,646
Loss from operations (6,486) (7,801) (20,267) (24,412)
Other income (expense):        
Interest income, net 1 1 1 2
Gain on settlement of debt 0 553 0 553
Loss before income taxes (6,485) (7,247) (20,266) (23,857)
Income taxes (benefit) 0 0 0 0
Net loss (6,485) (7,247) (20,266) (23,857)
Non-controlling interest 113 (6) 172 584
Net loss attributable to BioSig Technologies, Inc. (6,372) (7,253) (20,094) (23,273)
Preferred stock dividend (2) (2) (7) (7)
Preferred stock deemed dividend (17) 0 (125) 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (6,391) $ (7,255) $ (20,226) $ (23,280)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.14) $ (0.21) $ (0.5) $ (0.71)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 45,015,574 34,856,502 40,311,669 32,881,932
Product [Member]        
Revenue $ 127 $ 100 $ 127 $ 414
Service [Member]        
Revenue $ 8 $ 8 $ 24 $ 19

Source